OCGN250516C500
- 0.31
- +0.04+14.81%
Ocugen Newsroom
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Ocugen Inc. Stock Rises Thursday, Outperforms Market
Ocugen Inc. Stock Sheds 6.5%, Underperforms Market
Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?
Ocugen Inc. Stock Advances 4.1%, Outperforms Market
Prelude to increased tariffs? The Trump administration has initiated a Section 232 investigation into pharmaceuticals and Semiconductors.
① The USA government disclosed on Monday that it has launched an investigation into the impact of imported Pharmaceuticals and Semiconductors on National Security; ② This is widely seen as a prelude to imposing tariffs on prescription drugs and Semiconductors, and it could further escalate the trade war initiated by the USA.
Ocugen Management to Meet With Maxim
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
Ocugen Inc. Stock Rises Wednesday, Outperforms Market
Ocugen Inc. Stock Advances 6.5%, Outperforms Market
Ocugen's Strategic Advancements and Promising Developments Justify Buy Rating
Ocugen Advances OCU200 Trial After Safety Board Review
Express News | Ocugen Inc - to Complete Phase 1 Ocu200 Trial in Second Half of 2025
Express News | Ocugen Inc - Ocu200 Shows Favorable Safety Profile, No Serious Adverse Events Reported
Express News | Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of Ocu200—a Novel Fusion Protein for Diabetic Macular Edema
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
Ocugen Inc. Stock Rises 6.6%, Outperforms Market